<?xml version="1.0" ?>
<document id="f7bb1f005066cb4930f83cde4cdc1ff3fe411def">
  <chunk id="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c0" text="Overview of the 3rd isirv-Antiviral Group Conference - advances in clinical management"/>
  <chunk id="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1" text="This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference -advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.">
    <entity charOffset="227-236" id="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.e0" ontology_id="DOID_8469" text="influenza" type="disease"/>
    <entity charOffset="315-325" id="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.e1" ontology_id="CHEBI_22587" text="antivirals" type="chemical"/>
    <entity charOffset="358-367" id="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.e2" ontology_id="DOID_8469" text="influenza" type="disease"/>
    <pair e1="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.e0" e2="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.e1" id="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.p0" relation="true"/>
    <pair e1="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.e1" e2="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.e2" id="f7bb1f005066cb4930f83cde4cdc1ff3fe411def.c1.p1" relation="true"/>
  </chunk>
</document>
